

REFERENCES

- [1] Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. *J Am Soc Nephrol* 2006;17:2006–16.
- [2] Navaneethan SD, Pansini F, Strippoli GF. Statins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trials. *PLoS Med* 2006;3:e123.
- [3] Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. *Cochrane Database Syst Rev* 2009;CD007784.
- [4] ClinicalTrials.gov.PLANET1: prospective evaluation of proteinuria and renal function in diabetic patients with progressive renal disease. <http://clinicaltrials.gov/ct2/show/NCT00296374?term=planet&rank=1> [accessed 03.03.10].
- [5] Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? *Kidney Int* 1998;54:687–97.
- [6] Hara M, Yanagihara T, Takada T, Itoh M, Matsuno M, Yamamoto T, et al. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. *Am J Nephrol* 1998;18:35–41.
- [7] Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. *Nephrol Dial Transplant* 2000;15:1379–83.
- [8] Wu Y, Wang Y, An C, Dong Z, Liu H, Zhang Y, et al. Effects of rosuvastatin and atorvastatin on renal function: meta-analysis. *Circ J* 2012;76:1259–66.
- [9] Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, et al. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. *Am J Nephrol* 2000;20:175–9.
- [10] Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. *Am J Nephrol* 2000;20:373–9.
- [11] Kihara I, Tsuchida S, Yaoita E, Yamamoto T, Hara M, Yanagihara T, et al. Podocyte detachment and epithelial cell reaction in focal segmental glomerulosclerosis with cellular variants. *Kidney Int Suppl* 1997;63:S171–6.
- [12] Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. *J Am Soc Nephrol* 2006;17:754–64.
- [13] Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. *Am J Cardiol* 2005;96:11F–23F.
- [14] Mason RP, Walter MF, Day CA, Jacob RF. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. *J Biol Chem* 2006;281:9337–45.
- [15] Golbidi S, Ebadi SA, Laher I. Antioxidants in the treatment of diabetes. *Curr Diabetes Rev* 2011;7:106–25.
- [16] Giacco F, Brownlee M. Oxidative stress and diabetic complications. *Circ Res* 2010;107:1058–70.

